Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Kimberly Blackwell MD

Kimberly L Blackwell MD

Professor of Medicine and Assistant Professor in Radiation Oncology, Duke Department of Medicine, Durham, NC

Dr. Blackwell is the director of the Duke University breast cancer group where she supervises the clinical operations and the conduct of over 50 translational and therapeutic trials in breast cancer. She is well recognized as a national leader in early phase clinical trial design, early phase drug development, and translational biomarker development in breast cancer. She is currently a Susan G. Komen Research Scholar. She has been the principle investigator on over 40 clinical trials in metastatic breast cancer, and the co-investigator on multiple large correlative science projects. She was the principle investigator on the pre-clinical, phase 2, and phase 3 studies that led to the approval of lapatinib for the treatment of HER2 overexpressing breast cancer.

Disclosures

Kimberly L. Blackwell, MD serves as a consultant/advisory board member for Amgen Inc., Celgene Corp., Eli Lilly and Co., Genentech, USA, F. Hoffmann-La Roche Ltd., Novartis Pharmaceuticals, Inc., Pfizer, Inc., Spectrum Pharmaceuticals, Inc., Advaxis, Inc., Bayer Healthcare Pharmaceuticals, Inc., Puma Biotechnology, Inc., Incyte Corp., and Sandoz, Inc.; and serves as a principal investigator where her institution receives research grant support from Novartis Pharmaceuticals, Inc., Pfizer, Inc., Genentech, USA, and Celgene Corp.

Recent Contributions to PracticeUpdate:

  1. Adding Anthracyclines to the Adjuvant Treatment of Breast Cancer: Data Review and Practical Implications
  2. HER2+ Cancer Treatment: Resistance, Immunologic Implications, and Biosimilars
  3. Implications for Treatment of Estrogen Receptor Mutations
  4. New Data and New Drugs for Metastatic Breast Cancer: Recommendations by Patient Subtype
  5. SABCS 2015: Recommendations From Dr. Kimberly Blackwell
  6. SABCS 2015: More Recommendations From Dr. Kimberly Blackwell
  7. ASCO 2015 Recap: Dr. Kimberly Blackwell Circles Back to HER2/ER Breast Cancer—Part 1
  8. ASCO 2015 Recap: Dr. Kimberly Blackwell Circles Back to HER2/ER Breast Cancer—Part 2
  9. Dr. Kimberly Blackwell’s 2015 ASCO Abstract Recommendations—Breast Cancer: HER2/ER Disease
  10. Dr. Kimberly Blackwell’s ASCO 2014 LBA Picks for Breast Cancer: HER2/ER Disease

Most Read This Week

Recently Updated